T1	Participants 44 107	in patients with acute ischaemic stroke and atrial fibrillation
T2	Participants 212 272	Patients with acute ischaemic stroke and atrial fibrillation
T3	Participants 510 789	multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation
